Publications

Bhattarai K, Majer T, Haussmann M, Schollmeyer D, Oni FE, Höfte M, Voget R, Gütschow M, Ruetalo N, Schindler M, Straetener J, Wannenwetsch T, Brötz-Oesterhelt H, Karongo R, Lämmerhofer M, Hennessy RC, Muletz-Wolz CR, Gross H; Salamandamide Lipodipeptides are Biosynthetic Intermediate Shunt Products of the Nonamodular Nonribosomal Peptide Assembly Lines of the Viscosin Family; J. Nat. Prod. 2025, 88, 1012-1022. 

Steinebach C., Bricelj A., Murgai A., Sosič I., Bischof L., Ng Y. L. D., Bischof C., Heim C., Maiwald S., Proj N., Voget R., Feller F., Košmrlj J., Sapozhnikova V., Schmidt A., Zuleeg M. R., Lemmitzer P., Mertins P., Hansen F. K., Gütschow M., Krönke J., Hartmann M. D. Leveraging Ligand Affinity and Properties: Discovery of Novel Benzamide-Type Cereblon Binders for the Design of PROTACs. J. Med. Chem. 2023, 66, 14513–14543.

Bockstiegel J., Wurnig S. L., Engelhardt J.,  Enns J., Hansen F. K., Weindl G. Pharmacological inhibition of HDAC6 suppresses NLRP3 inflammasome-mediated IL-1β release. Biochem. Pharmacol. 2023. 215: 115693. doi: 10.1016/j.bcp.2023.115693

Kraft F. B., Enns J., Honin I., Engelhardt J., Scholer A., Smith S. T., Meiler J., Schäker-Hübner L., Weindl G., Hansen F. K. Groebke Blackburn Bienaymé-mediated multi-component synthesis of selective HDAC6 inhibitors with anti-inflammatory properties. Bioorg. Chem. 2024, 143, 107072.

Flury P., Breidenbach J., Krüger N., Voget R., Schäkel L., Si Y., Krasniqi V., Calistri S., Olfert M., Sylvester K., Rocha C., Ditzinger R., Rasch A., Pöhlmann S., Kronenberger T., Poso A., Rox K., Laufer S. A., Müller C. E., Gütschow M., Pillaiyar T. Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity. ACS Pharmacol. Transl. Sci. 2024 , 7, 493-514.

Breidenbach J., Voget, R., Si, Y., Hingst, A., Claff, T., Sylvester, K., Wolf, V., Krasniqi, V., Useini, A., Sträter, N., Ogura, Y., Kawaguchi, A., Müller, C. E., Gütschow, M. Macrocyclic Azapeptide Nitriles: Structure-Based Discovery of Potent SARS-CoV-2 Main Protease Inhibitors as Antiviral Drugs. J. Med. Chem. 2024, 67, 11, 8757–8790.

Voget, R., Breidenbach, J., Claff, T., Hingst, A., Sylvester, K., Steinebach, C., Vu, L. P., Weiße, R. H., Bartz, U., Sträter, N., Müller, C. E., Gütschow, M. Development of an Active-site Titrant for SARS-CoV-2 Main Protease as an Indispensable Tool for Evaluating Enzyme Kinetics. Acta Pharm. Sin. B 2024, 14, 2349–2357.

Kostenis E., Jürgenliemke, L., Alenfelder J. G protein-mediated signal transduction: a molecular choreography of G protein activation after GTP binding. Signal Transduction and Targeted Therapy 2024, 9,188.

Brands J., Bravo S., Jürgenliemke L., Grätz L., Schihada H., Frechen F., Alenfelder J., Pfeil C., Ohse P. G., Hiratsuka S., Kawakami K., Schmacke L. C., Heycke N., Inoue A., König G., Pfeifer A., Wachten D., Schulte G., Steinmetzer T., Watts V. J., Gomeza J., Simon K., Kostenis E. A molecular mechanism to diversify Ca²⁺ signaling downstream of Gs protein-coupled receptors. Nat Commun. 2024, 15, 7684.

Mühle J., Rodrigues M.J., Alenfelder J., Jürgenliemke L., Guixà-González R., Bacchin A., Andres F., Hennig M., Schihada H., Crüsemann M., König G.M., Kostenis E., Schertler G., Deupi X. Cyclic peptide inhibitors stabilize Gq/11 heterotrimers. bioRxiv 2024, doi.org/10.1101/2023.10.24.563737.

Meringdal J. W., Bade L., Bendas G., Menche D. Diversity Oriented Synthesis of Novel Xanthones Reveal Potent Doxorubicin-Inspired Analogs. ChemMedChem 2024, doi.org/10.1002/cmdc.202400055.

Feller F., Honin I., Miranda M., Weber H., Henze S., Hanl M., Hansen F. K. Development of the First-in-Class FEM1B-Recruiting Histone Deacetylase Degraders.
J Med Chem 2025, doi: 10.1021/acs.jmedchem.4c02569.

Keuler T., Ferber D., Engelhardt J., Steinebach C., Kirsch N., Marleaux M., Weindl G., Geyer M., Gütschow M. Degrading the Key Component of the Inflammasome: Development of an NLRP3 PROTAC. Chem. Commun. 2025, 61, 3001-3004.

König B., Watson, P. R. Reßing N., Cragin A. D., Schäker-Hübner L., Christianson D. W., Hansen F. K. Difluoromethyl-1,3,4-oxadiazoles Are Selective, Mechanism-Based, and Essentially Irreversible Inhibitors of Histone Deacetylase 6. J. Med. Chem. 2023, 66, 13821-13837. 

Jenke, R., Oliinyk, D.m Zenz, T., Körfer, J., Schäker-Hübner, L., Hansen, F. K., Lordick, F., Meier-Rosar, F., Aigner, A., Büch, T. HDAC inhibitors activate lipid peroxidation and ferroptosis in gastric cancer. Biochem. Pharmacol. 2024, 225, 116257.

Scheuerer, S., Motlova, L., Schäker-Hübner, L., Sellmer, A., Feller, F., Ertl, F. J., Koch, P., Hansen, F. K., Barinka, C, Mahboobi, S. Biological and structural investigation of tetrahydro-β-carboline-based selective HDAC6 inhibitors with improved stability. Eur. J. Med. Chem. 2024, 276, 116676.

 Fischle A., Lutsch M., Hübner F., Schäker‑Hübner L., Schürmann L., Hansen F. K., Kalinina S. A. Micro-scale screening of genetically modifed Fusarium fujikuroi strain extends the apicidin family. Nat. Prod. Bioprospect. 2024, 14, 1-20.

Toledano-Pinedo M., Porro-Pérez A., Schäker-Hübner L., Romero F., Dong M., Samadi A., Almendros P., Iriepa I., Bautista-Aguilera O. M., Rodríguez-Fernández M. M., Solana-Manrique C., Sanchis I., Mora-Morell A., Canseco Rodrìguez A., Sànchez-Pérez A. M., Knez D., Gobec S., Bellver-Sanchis A., Pérez B., Dobrydnev A. V.m Artetxe-Zurutuza A., Matheu A., Siwek A., Wolak M., Satała G., Bojarski A. J., Doroz-Płonka A., Handzlik J., Godyń J., Więckowska A., Paricio N., Griñán-Ferré C., Hansen F. K., Marco-Contelles J. Contilisant+Tubastatin A Hybrids: Polyfunctionalized Indole Derivatives as New HDAC Inhibitor-Based Multitarget Small Molecules with In Vitro and In Vivo Activity in Neurodegenerative Diseases. J. Med. Chem. 2024, 67, 16533-55. 

Kraft F. B., Biermann L., Schäker-Hübner L., Hanl M., Hamacher A., Kassack M. U., Hansen F. K. Hydrazide-Based Class I Selective HDAC Inhibitors Completely Reverse Chemoresistance Synergistically in Platinum-Resistant Solid Cancer Cells J. Med. Chem. 2024, doi: 10.1021/acs.jmedchem.4c01817. 

Bollmann L. M., Lange F., Hamacher A., Biermann L., Schäker-Hübner L., Hansen F. K., Kassack M. U. Triple Combination of Entinostat, a Bromodomain Inhibitor, and Cisplatin Is a Promising Treatment Option for Bladder Cancer. Cancers 2024; 16, 3374. 

Stopper D., Buntrock S., Tan K., Carvalho L. P. de, Schäker-Hübner L., Held J., Kassack M. U., Hansen F. K. Multicomponent syntheses enable the discovery of novel quisinostat-derived chemotypes as histone deacetylase inhibitors. Eur J Med Chem 2025, doi: 10.1016/j.ejmech.2024.117045.

Al Hamwi G, Alnouri MW, Verdonck S, Leonczak P, Chaki S, Frischbutter S, Kolkhir P, Michaela Matthey M, Kopp C, Bednarski M, Riedel YK, Marx D, Clemens S, Namasivayam V, Gattner S, Thimm D, Sylvester K, Wolf K. Kremer AE, De Jonghe S, Wenzel D, Kotańska M, Ali H, Herdewijn P, Müller CE. Subnanomolar MAS-related G protein-coupled receptor-X2/B2 antagonists with efficacy in human mast cells and disease models; Signal Transduction and Targeted Therapy. DOI: 10.1038/s41392-025-02209-8

Sinatra L., Vogelmann A., Friedrich F., Tararina M. A., Neuwirt E., Colcerasa A., König P., Toy L., Yesiloglu T. Z., Hilscher S., Gaitzsch L., Papenkordt N., Zhai S.,  Zhang L., Romier C., Einsle O., Sippl W., Schutkowski M., Gross O., Bendas G., Christianson D. W., Hansen F. K., Jung M., Schiedel M. Development of First-in-Class Dual Sirt2/HDAC6 Inhibitors as Molecular Tools for Dual Inhibition of Tubulin Deacetylation. J. Med. Chem. 2023, 66, 14787-14814.

Huber M. E., Wurnig S., Toy L., Weiler C., Merten N., Kostenis E., Hansen F. K., Schiedel M. Fluorescent Ligands Enable Target Engagement Studies for the Intracellular Allosteric Binding Site of the Chemokine Receptor CXCR2. J. Med. Chem. 2023, 66, 9916-9933.

Wollnitzke P., Wagner R., Afsar S. Y., Werner M., Geschold R., Müller C. E., Werz O., van Echten-Deckert G., Menche D. Synthesis and biological evaluation of simplified ajudazol derivatives reveal potent 5-lipoxygenase inhibition and considerable apoptotic activity in neuroblastoma cells. Bioorg. Med. Chem. Lett. 2023, doi.org/10.1016/j.bmcl.2023.129464

Hanke W., Alenfelder J., Liu J., Gutbrod P., Kehraus S., Crüsemann M., Dörmann P., Kostenis E., Scholz M., König G. M. The Bacterial Gq Signal Transduction Inhibitor FR900359 Impairs Soil-Associated Nematodes. J. Chem. Ecol, 2023, 49, 549-569.

Yamauchi, Y., Konno, S., Noriko, N., Yoshioka, N., Hingst, A., Gütschow, M., Müller, C. E., Taguchi, A., Taniguchi, A., Kawaguchi, A., Hayashi, Y. Detection of Active SARS-CoV-2 3CL Protease in Infected Cells using Activity-based Probes with a 2,6-Dichlorobenzoyloxymethyl Ketone Reactive Warhead. ACS Chem. Biol. 2024, 19, 1028–1034.

Huber, M. E., Wurnig, S. L., Moumbock, A. F. A., Toy, L., Kostenis, E., Alonso Bartolomé, A., Szpakowska, M., Chevigné, A., Günther, S., Hansen, F. K., Schiedel, M. Development of a NanoBRET Assay Platform to Detect Intracellular Ligands for the Chemokine Receptors CCR6 and CXCR1. ChemMedChem 2024, DOI: 10.1002/cmdc.202400284.

Oneto A., Hamwi G. A., Schäkel L., Krüger N., Sylvester K., Petry M., Shamleh R. A., Pillaiyar T., Claff T., Schiedel A. C., Sträter N., Gütschow M., Müller C. E. Nonpeptidic Irreversible Inhibitors of SARS-CoV-2 Main Protease with Potent Antiviral Activity. J. Med. Chem. 2024 , 67, 14986-15011.

Flury, P., Krüger, N., Sylvester, K., Breidenbach, J., Al Hamwi, G., Qiao, J., Chen, Y., Rocha, C., Sá Magalhães Serafim, M., Barbosa da Silva, E., Pöhlmann, S., Poso, A., Kronenberger, T., Rox, K., O’Donoghue, A. J., Yang, S., Sträter, N., Gütschow, M. Laufer, S. A., Müller, C. E., Pillaiyar, T. Design, Synthesis, and Unprecedented Interactions of Covalent Dipeptide-Based Inhibitors of SARS-CoV‑2 Main Protease and Its Variants Displaying Potent Antiviral Activity. J. Med. Chem. 2025, 68, 3626-3652.

Lewis, K., Lee, R. E., Brötz-Oesterhelt, H., Hiller, S., Rodnina M. V., Schneider, T., Weingarth, M., Wohlgemuth, I. Sophisticated natural products as antibiotics, Nature 2024, 632, 39-49.